Citadel Advisors’s Exagen XGN Stock Holding History
Bought
Maintained
Sold
Other funds holding XGN
NCNMGF
MBAM
Citadel Advisors's XGN Position: Q3 2026 in Review
Citadel Advisors increased its Exagen (XGN) stake by 1,802% in Q3 2026, buying an estimated $1.67M and bringing the position to 273,804 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #6481.
Citadel Advisors first reported a position in XGN in Q2 2022 and has held it in 12 quarters since. 78 funds tracked by Wall St. Rank hold XGN as of Q3 2026.
- Citadel Advisors held 273,804 shares of Exagen worth $2.23M as of Q3 2026.
- Citadel Advisors bought 259,411 Exagen shares in Q3 2026, an estimated $1.67M.
- Exagen made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6481 holding.
- Citadel Advisors first reported a position in Exagen in Q2 2022 and has held it in 12 quarters since.
- 78 funds tracked by Wall St. Rank held Exagen as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.